Tumor necrosis factor receptor-associated factor 3 (TRAF3) is a cytoplasmic protein that controls signal transduction from different receptor families, and plays a key role in regulating immunity.

A fusion protein removed beta-amyloid plaque without producing the neurotoxic inflammation associated with other treatments, such as aducanumab immunotherapy. It is based on the alphaA Beta-Gas6 fusion protein developed in a mouse model of Alzheimer's disease (AD) by a team of researchers at The Korea Advanced Institute of Science and Technology (KAIST) in South Korea.

Working to overcome the short circulatory half-lives of platinum drugs in vivo, researchers at Shenzhen University and the City University of Hong Kong have explored the use of a platinum(IV) prodrug to bind erythrocytes.

Gilead Sciences has presented substituted pyridotriazine compounds reported to be useful for the treatment of HIV infections.

Biofront Therapeutics has identified fMet-Leu-Phe receptor (fMLP; FPR1) antagonists reported to be useful for the treatment of glioblastoma, traumatic brain injury and stroke.

Earth Chemical has patented lipoprotein lipase (LPL) activators reported to be useful for the treatment of hypertriglyceridemia. An exemplified compound rescued LPL from N-terminal GST-tagged angiopoietin-like 4 (ANGPTL4)-induced inactivation (EC50 = 1.01 mcM) in fluorescence-based assays.

Viking Therapeutics has divulged dual agonists of GLP-1 and glucose-dependent insulinotropic receptor (GDIR) reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD).

Baylor College of Medicine has disclosed bromodomain testis-specific protein (BD2 domain) (BRDT-BD2) inhibitors reported to be useful for the treatment of male contraception and male infertility.

Chemokines are small signaling cytokines that are involved in many physiological processes such as host immune responses, wound healing and bone remodeling, with two of these chemokines, C-X-C motif chemokine 9 (CXCL9) and CXCL10, being involved in different osteoimmuno-modulating pathways.

Jemincare and its wholly owned subsidiary Shanghai Jemincare Pharmaceutical have signed an exclusive worldwide license agreement with Roche and Genentech for the development and commercialization of the androgen receptor degrader JMKX-002992.